These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 16023651)

  • 1. Clots, kinins and coronaries.
    Cruden NL; Newby DE
    Atherosclerosis; 2005 Dec; 183(2):189-98. PubMed ID: 16023651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease.
    Vaughan DE
    Eur Heart J; 1998 Jul; 19 Suppl G():G9-12. PubMed ID: 9717049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans.
    Oliver JJ; Webb DJ; Newby DE
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2470-9. PubMed ID: 16210566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb.
    Cruden NL; Lang NN; MacGillivray TJ; Uren NG; Fox KA; Newby DE
    Heart Vessels; 2012 Mar; 27(2):179-85. PubMed ID: 21394642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous tissue plasminogen activator enhances fibrinolysis and limits thrombus formation in a clinical model of thrombosis.
    Lucking AJ; Gibson KR; Paterson EE; Faratian D; Ludlam CA; Boon NA; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2013 May; 33(5):1105-11. PubMed ID: 23471234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors.
    Auch-Schwelk W; Kuchenbuch C; Claus M; Walther B; Bossaller C; Friedel N; Graf K; Gräfe M; Fleck E
    Eur Heart J; 1993 Nov; 14 Suppl I():154-60. PubMed ID: 8293767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
    Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
    J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure.
    Hornig B; Arakawa N; Drexler H
    Eur Heart J; 1998 Jul; 19 Suppl G():G48-53. PubMed ID: 9717056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass.
    Pretorius M; McFarlane JA; Vaughan DE; Brown NJ; Murphey LJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):379-87. PubMed ID: 15470338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
    Cruden NL; Tse GH; Fox KA; Ludlam CA; Megson I; Newby DE
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):772-7. PubMed ID: 15681300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of ACE inhibitors versus AT1 blockers.
    Vaughan D
    Can J Cardiol; 2000 Aug; 16 Suppl E():36E-40E. PubMed ID: 10906625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition.
    Mombouli JV; Vanhoutte PM
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S74-82. PubMed ID: 1282634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Blood coagulation and fibrinolysis in arteriosclerosis].
    Hoffmeister HM; Heller W; Seipel L
    Z Kardiol; 1999 May; 88(5):315-23. PubMed ID: 10413853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variation and gender determine bradykinin type 1 receptor responses in human tissue: implications for the ACE-inhibitor-induced effects in patients with coronary artery disease.
    Wu H; Roks AJ; Leijten FP; Garrelds IM; Musterd-Bhaggoe UM; van den Bogaerdt AJ; de Maat MP; Simoons ML; Danser AH; Oeseburg H
    Clin Sci (Lond); 2014 Mar; 126(6):441-9. PubMed ID: 24117346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effects of glucocorticoids on endothelial fibrinolytic and vasodilator function in humans.
    Dover AR; Hadoke PW; Walker BR; Newby DE
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):321-6. PubMed ID: 17878762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors unmask endogenous kinin production by bovine coronary artery endothelium.
    Hecker M; Bara AT; Busse R
    Eur Heart J; 1993 Nov; 14 Suppl I():161-3. PubMed ID: 8293768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitors.
    de Graeff PA; van Gilst WH
    Agents Actions Suppl; 1992; 38 ( Pt 3)():110-8. PubMed ID: 1462853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition.
    Vaughan DE
    Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-34-7. PubMed ID: 9422850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema.
    Bas M; Kirchhartz N; Hochfeld J; Tüllmann C; Kumpf S; Suvorava T; Oppermann M; Hafner D; Bier H; Hoffmann TK; Balz V; Kojda G
    J Allergy Clin Immunol; 2008 Apr; 121(4):969-75.e2. PubMed ID: 18395553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.